

Nonprofit corporations and independent licensees of the Blue Cross and Blue Shield Association

How to submit prior authorization requests for medical benefit drugs

For Blue Cross commercial and Blue Care Network commercial

January 2025

Follow these steps to submit prior authorization requests when prescribing drugs covered under the medical benefit for Blue Cross Blue Shield of Michigan and Blue Care Network commercial members.

Michigan prescribers

To submit prior authorization requests electronically, first register for Availity® Essentials, our provider portal; refer to the Register for web tools page at bcbsm.com for details. Then:

- 1. Log in to availity.com*.
- Click Payer Spaces on the menu bar and click the BCBSM and BCN logo.
- On the Applications tab, click the tile for the appropriate NovoLogix web tool.
- Within NovoLogix, click the Authorizations menu and select Create Authorization.
- Enter the member's details and select the correct member on the contract.
- Complete the required fields. This includes selecting the correct drug in the "Authorization Lines" section.
- 7. Click Submit, complete the protocol questions and click Done.

If you're registered for Availity but are not able to access it, submit your prior authorization request using the *Medication Authorization Request Form*, or MARF, that's on the next page.

Non-Michigan prescribers

When submitting a prior authorization request for the first time, prescribers located outside of Michigan should complete and submit:

- The Medication Authorization Request Form, or MARF, that's on the next page
- The Application for access to NovoLogix for non-Michigan prescribers

Submit these documents to the fax number or address that's on the MARF. Once we approve the request for access, we'll provide information about how to access the NovoLogix tool so that you can submit subsequent prior authorization requests electronically.

Note: Access to NovoLogix is available only to registered users. You must include a valid Type 1 (individual) NPI on the application for access to NovoLogix.

Information about NovoLogix

For more information about the NovoLogix web tool, look under the Training Resources heading on these webpages:

- Blue Cross Medical-Benefit Drugs
- BCN Medical-Benefit Drugs

If you need help with the NovoLogix tool, contact the Web Support Help Desk at 1-877-258-3932.

*Clicking this link means that you're leaving the Blue Cross Blue Shield of Michigan and Blue Care Network website. While we recommend this site, we're not responsible for its content.

Availity[®] is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to offer provider portal services.

Blue Cross Blue Shield/Blue Care Network of Michigan **Medication Authorization Request Form**

Aflibercept Products

Eylea® (aflibercept): J0178, Eylea HD (aflibercept): J0177, Ahzantive: J3590, Opuviz: J3590, Yesafili: J3590



Nonprofit corporations and independent licensees of the Blue Cross and Blue Shield Association

This form is to be used by participating physicians to obtain coverage for Eylea and Eylea HD. For commercial members only, please complete this form and submit via fax to 1-877-325-5979. If you have any questions regarding this process, please contact BCBSM Provider Relations and Servicing or the Medical Drug Helpdesk at 1-800-437-3803 for PHYSICIAN INFORMATION PATIENT INFORMATION Name Name Specialty ID Number Address ☐Male ☐Female D.O.B. City /State/Zip Diagnosis Phone/Fax: P: (Drug Name Dose and Quantity Contact Person Directions Contact Person Phone / Date of Service(s) **DISEASE STATE INFORMATION** STEP 1: Is this request for:
Initiation ☐ Continuation Date patient started therapy: 2. Please provide the NPI number for the place of administration: Initiation AND Continuation of therapy: What eye(s) will be treated? ☐ Left eye ☐ Right eye What is the patient's dose and frequency of requested medication? What is the patient's diagnosis? Neovascular (wet) age-related macular degeneration (AMD) ☐ Diabetic retinopathy (DR) ☐ Retinopathy of Prematurity (ROP- go to f) ☐ Other, Please specify: Macular edema due to retinal vein occlusion (RVO) Diabetic macular edema (DME) What is the visual acuity in the right eye? What is the visual acuity in the left eye? Has the patient tried Avastin or bevacizumab biosimilar intravitreal treatment? □ No ☐ Yes Which eye was treated? ☐ Left eye ☐ Right eye Please enter number of Avastin or a bevacizumab biosimilar injections patient has received and in which eye? ii. What was the patient's frequency of Avastin or bevacizumab biosimilar?

4 weeks

6 weeks

8 weeks

Other: Date of the last three Avastin or a bevacizumab biosimilar injection: What was the patient's outcome while on Avastin or bevacizumab biosimilar therapy? ☐ Visual acuity improvement ☐ Reduction in edema ☐ Decrease in retinal thickness ☐ Condition remained the same ☐ Worsening in visual acuity ☐ Increased edema ☐ Increase in retinal thickness ☐ Persistent edema ☐ Intolerance to the medication: ☐ Other, Please list: _ Has the patient failed treatment with other anti–VEGF therapy? ☐ Yes ☐ No i. If yes, List what treatment(s) patient failed: f Diagnosis of retinopathy of prematurity (ROP) only What is the patient's gestational age (weeks)? What is the patient's birth weight (kg)? What is the patient's current weight(kg)? What is the patient's ROP classified as? ROP Zone I Stage 1+, 2+, 3 or 3+ ☐ ROP Zone II Stage 2+ or 3+ ☐ Aggressive posterior ROP □ Other Continuation of therapy: How has the patient's condition changed while on therapy? ☐ Improved; Please describe: ☐ Stable: Please describe: ☐ Worsened; Please describe: ☐ Other; Please describe: Please add any other supporting medical information necessary for our review Coverage will not be provided if the prescribing physician's sign Physician's Name Pusly jeopardize the life or h ☐ Form Completely Filled Out ☐ Attached chart notes ☐ Pertinent test results By Mail: BCBSM Specialty Pharmacy Program Step 3: By Fax: BCBSM Specialty Pharmacy Mailbox

1-877-325-5979

P.O. Box 312320. Detroit. MI 48231-2320